Morysa (Memantine Hydrochloride)

Memantine hydrochloride, the active ingredient in Morysa, is a NMDA receptor antagonist presented as an oral dosage form for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults, where it helps to reduce excitotoxic neuronal damage associated with disease progression.

GNH USA supplies Morysa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to comprehensive quality standards and provides reliable sourcing for global regulated markets.

Memantine hydrochloride is used in the management of neurodegenerative disorders, specifically targeting the glutamatergic pathway in Alzheimer’s disease.

- Moderate to severe Alzheimer’s disease: helps maintain cognitive function and daily activities in patients with established disease. - Behavioral disturbances in Alzheimer’s disease: may reduce agitation and aggression associated with disease progression. - Dementia of various etiologies (off‑label): sometimes employed as an adjunct to address excitotoxic neuronal injury.

Memantine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate cranial pain. - Constipation: reduced bowel motility. - Confusion: transient disorientation or difficulty concentrating. - Fatigue: feeling unusually tired. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: serious skin and mucous membrane disorder. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Cardiac arrhythmia: irregular heart rhythm. - Psychosis: new or worsening hallucinations or delusional thoughts.

When prescribing memantine, clinicians should consider several safety factors.

- Renal impairment: assess kidney function and adjust dose if necessary. - History of seizures: monitor closely for increased seizure activity. - Cardiovascular disease: use with caution in patients with unstable heart conditions. - Concomitant NMDA antagonists: avoid combining with other agents that block NMDA receptors. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Memantine may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism can increase neurotoxicity. - Ketamine: combined NMDA blockade may cause profound central nervous system depression.

Moderate Interactions (Monitor Closely): - Anticholinesterases (e.g., donepezil, rivastigmine): may require dose adjustment for optimal efficacy. - CNS depressants (e.g., benzodiazepines): may enhance sedation and dizziness. - Diuretics (e.g., furosemide): may alter renal clearance of memantine.